In vitro culture, drug sensitivity, and transcriptome of plasmodium vivax hypnozoites

Publication Type:

Journal Article

Authors:

Nil Gural, Liliana Mancio-Silva, Alex B. Miller, Ani Galstian, Vincent L. Butty, Stuart S. Levine, Rapatbhorn Patrapuvich, Salil P. Desai, Sebastian A. Mikolajczak, Stefan H.I. Kappe, Heather E. Fleming, Sandra March, Jetsumon Sattabongkot, and Sangeeta N. Bhatia

Source:

Cell Host & Microbe, Volume 23, Issue 3, p.395-406 (2018)

URL:

http://www.cell.com/cell-host-microbe/fulltext/S1931-3128(18)30037-4

Abstract:

The unique relapsing nature of Plasmodium vivax infection is a major barrier to malaria eradication. Upon infection, dormant liver-stage forms, hypnozoites, linger for weeks to months and then relapse to cause recurrent blood-stage infection. Very little is known about hypnozoite biology; definitive biomarkers are lacking and in vitro platforms that support phenotypic studies are needed. Here, we recapitulate the entire liver stage of P. vivax in vitro, using a multiwell format that incorporates micropatterned primary human hepatocyte co-cultures (MPCCs). MPCCs feature key aspects of P. vivax biology, including establishment of persistent small forms and growing schizonts, merosome release, and subsequent infection of reticulocytes. We find that the small forms exhibit previously described hallmarks of hypnozoites, and we pilot MPCCs as a tool for testing candidate anti-hypnozoite drugs. Finally, we employ a hybrid capture strategy and RNA sequencing to describe the hypnozoite transcriptome and gain insight into its biology.

Manuscript

Supporting information

Previous
Previous

A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite

Next
Next

Personalized RNA-medicine for pancreatic cancer